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_______________________________________________________________  
The pharmaceutical industry is regulated by the Good Manufacturing Practices (GMP) 
and Good Laboratory Practices (GLP) in order to minimize the risks that might have an 
impact on the safety of the patients. The purpose of the regulations is to assure, that the 
pharmaceutical products meet the safety requirements and have the intended product 
identity, quality and purity characteristics. Regulations are regulating and covering the 
whole manufacturing process from the used premises and starting materials to the 
manufacturing process and final product and disposal of the product.  
 
This study aim was to optimize the pharmaceutical biotechnology company FIT 
Biotech’s Finn-Medi 3 building laboratory premises to meet the assessed quality 
requirements. The study objectives was to evaluate how to implement the appropriate 
quality requirements of different laboratory activities in accordance with GLP/GMP 
regulations. Additionally laboratory system efficiency, working practices and work 
safety was evaluated before and after the optimization of the laboratories was 
performed. The impact of the laboratory optimization process was studied through 
internal audits and the questionnaire was used as a self-evaluation tool for evaluating 
personnel perspectives of the optimization project.  
 
The experimental work consisted of the laboratory optimization project, where selected 
laboratory rooms were optimized to a higher quality level as deemed necessary by their 
intended use. As a result of the optimization project, all optimized laboratory rooms 
were meeting the set quality level at the time of the second audit. Only few quality 
related documents were still under updating at the time of the performance of the second 
audit. The quality level of the Finn-Medi 3 laboratory premises were noticed to be 
improved and conducting the audit. Audit as a method of evaluation, was noticed to be 
sufficient for detecting even small deficiencies in the laboratories. Questionnaire results 
partly supported the audit results, but due to the limited participants wich completed the 
queries it was difficult to draw any conclusions from the feedback obtained. However, 
from the evaluation of the completed questionnaires it was indicative that the 
optimization project influenced to the improved quality level of premises and work 
practices and result verified also by the audit conducted.  
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_______________________________________________________________  
Lääketeollisuudessa lääkkeiden valmistus on tarkoin säädeltyä GMP (Good 
Manufacturing Practice) ja GLP (Good Laboratory Practice) säädöksissä. Sääntelyn 
tarkoituksena on vähentää lääkkeiden käytöstä johtuvaa turvallisuusriskiä ja varmistaa, 
että lääkinnällinen tuote vastaa asetettuja turvallisuusmääräyksiä ja tuotteella on sille 
tarkoitetut ominaisuudet sekä että se täyttää sille asetetut laatu- ja puhtausvaatimukset. 
Säädökset kattavat koko tuotantoprosessin tuotantotiloista ja raaka-aineista aina 
valmiiseen tuotteeseen ja tuotteen hävitykseen saakka.   
 
Tässä työssä bioteknologia lääkeyrityksen FIT Biotech:n Finn-Medi 3 rakennuksessa 
sijaitsevat laboratoriotilat optimoitiin vastaamaan niille asetettuja tiukentuneita 
laatuvaatimuksia. Työn tarkoituksena oli kartoittaa kuinka päivitetyissä 
laboratoriotiloissa GLP/GMP laatuvaatimukset voitaisiin parhaiten toteuttaa. 
Laboratorioiden toiminta, työkäytännöt ja työsuojeluun liittyvät asiat kartoitettiin ennen 
ja jälkeen laboratorioiden optimoinnin. Henkilökunnan kokemuksia laboratorioiden 
optimointiprojektista kartoitettiin laboratoriotilojen päivityksen jälkeen tehtävällä 
kyselyllä.   
 
Työn käytännön osuuden muodosti laboratorioiden optimointi projekti, jossa tietyt 
laboratoriohuoneet optimoitiin vastaamaan nykyistä tarkoitustaan. Optimoinnin 
jälkeisessä auditoinnissa todettiin, että kaikki muutetut laboratoriohuoneet täyttivät 
niille asetetut laatuvaatimukset. Kokonaisuudessaan Finn-Medi 3:n laboratoriotilojen 
laadun todettiin parantuneen ja auditoinnin todettiin olevan sovelias menetelmä 
GLP/GMP sääntöjen noudattamisen kartoittamiseksi. Auditoinnissa ilmeni vain 
muutamia laadunvalvontaan liittyvien dokumenttien puuttumista.  Kyselyn tulokset 
tukivat osittain auditoinnista saatuja tuloksia, mutta kyselyn perusteella ei voitu tehdä 
lopullisia johtopäätöksiä optimoinnin vaikutuksesta kyselyyn vastanneiden vähäisen 
henkilömäärän vuoksi. Kyselyn tulokset kuitenkin viittasivat siihen, että laboratorioiden 
optimoinnilla on ollut positiivisia vaikutuksia laadun parantumisen ja työkäytäntöjen 
kehittymisen suhteen.  
 
_______________________________________________________  
Asiasanat: Good manufacturing practice, laboratoriotilojen optimointi projekti, auditointi  
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1. INTRODUCTION 
 
 
The pharmaceutical industry is regulated by the Good Manufacturing Practices (GMP) 
and Good Laboratory Practices (GLP) in order to minimize the risks that might have an 
impact on the safety of the patients. The purpose of the regulations is to assure, that the 
pharmaceutical products meet the safety requirements and have the intended product 
identity, quality and purity characteristics. This requires continuous quality monitoring 
in laboratory premises and work practices to assure that there are intended for the 
purpose and are meeting the applied requirements. Since workload in the 
pharmaceutical companies and tendency to have continuous change in laboratory 
activities have significantly increased, in order to maintain a high quality level of the 
manufacturing process and its productivity, laboratory facilities and workflow have to 
be critically reviewed frequently taking into account the quality requirements and work 
safety of the specific laboratory type.  
 
In laboratory evaluation and optimization process laboratory personnel are challenged to 
work jointly for achieving compliant results as well as increasing the knowledge of 
implementing regulations in practice.  Pharmaceutical companies should evaluate their 
laboratories from the operations and maintenance perspective jointly with the laboratory 
personnel for ensuring personnel awareness of quality requirements and safe laboratory 
practices (Modica 2007, 25). It seems, that quality auditing alone may not be sufficient 
method for performing laboratory utilization projects, but combining it to the staff 
education and supported by the administration and its feedback system, it increases the 
success of the laboratory utilization projects (Calderon-Margalit, Mor-Yosef, Mayer, 
Adler & Shapira. 2005. 243). Repeat cycles of the clinical audits combined with the 
personnel active role and the administrative support in improvement projects and 
empowerment of the personnel, increases the personnel competence and quality of the 
work unit (Ved & Coupe 2007, 294).  
 
In this study the pharmaceutical biotechnology company FIT Biotech’s Finn-Medi 3 
building laboratory premises were updated to support the current laboratory activities 
and meet the quality requirements according to FIT Biotech’s internal audit 
recommendations.  
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Audit was used to evaluate how to apply appropriate quality requirements per specific 
laboratory type and for evaluation of the quality level of the laboratories. Laboratory 
premises were updated according first audit recommendations in laboratory 
optimization project. Nine months after the optimization project of the laboratories, 
laboratory premises were audited for evaluation of quality, laboratory work practices 
and laboratory safety. - To evaluate how to improve the laboratory system efficiency, 
working practices and work safety.  
 
Questionnaire result was used as a self-evaluation tool as well assessment tool to 
evaluate the feedback regarding the impact of the optimization project. Questionnaire 
resulted feedback how optimization project was affected to the quality of the premises, 
work practices and work safety.   
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2. THEORETICAL FRAMEWORK 
 
 
Pharmaceutical companies are regulated by the law for ensuring the safety of the 
medical products. For ensuring the safety and quality of the manufacturing process, 
pharmaceutical companies have to follow specific quality requirements wich have an 
impact of the whole management and manufacturing process of the company. The 
current Good Manufacturing Practices (GMP) regulations were originally generated by 
the Federal Food and Drug Administration (FDA) in the United States of America 
(USA). Governmental surveys revealed in the 1970’s, that pharmaceutical company’s 
clinical research documentation had serious reliability problems. As a survey result, and 
with the other criteria, modern GLP regulations were then established in 1976. 
(Anderson 2000, 5.) The regulations were later adopted into Europe, where European 
Medicinal Agency (EMA) started to control the pharmaceutical industry in the same 
manner. Both agency’s tasks are to ensure, that the regulated industries comply with a 
total quality control concept through it’s manufacturing process. The responsibility to 
comply with the requirements is determined by the law. (Willig, Tuckerman & 
Hitchings 1982, 2.)  
 
Adherence to the regulations is a minimum requirement, but it does not ensure, that the 
manufacturer is in compliance. In addition, manufacturer is bound to continuous 
practices and processes improvements. Thus, if a new practice is introduced anywhere 
in the industry which is better than the current one, manufacturers may seem obligated 
to adopt the better practice or improve own practices into same level. (Willig, et.al. 
1982, 4.) New practices must be evaluated frequently for ensuring the compliance of the 
changed item. For example product, premises or manufacturing process can be audited 
with different type of audits. Audit is defined as “A planned, independent, and 
documented assessment to determine whether agreed requirements are being met and it 
is essential tool for pharmaceutical company for evaluation of quality, work practices 
and safety of the laboratory premises. (Russel 2000, xxvi.) 
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2.1. Quality Assurance (QA) 
 
GLP as well as GMP states, that the pharmaceutical company should have a Quality 
Assurance Unit (QAU), that is responsible for monitoring each study to assure that the 
management of facilities, equipments, personnel, methods, practices, records and 
controls conform within the regulations (ref. EMA/FDA Guidelines). QAU is not 
specifically designated to address the technical items of the study, but rather to assure 
conformity with the procedural and administrative requirements.  
 
QAU develop strategy, policy and standards on how to implement quality regulations 
and standards on operational level. QAU monitors by auditing implementation of 
processes and proper applications, ensures that the specification, production master 
formula, or other procedures impacting the product are approved and deviations from 
the procedures are documented. Quality assurance approves contract manufacturers, 
review and approves validation protocols and reports, makes sure that quality related 
complaints are investigated and resolved, effective systems for maintaining and 
calibrations of the equipments are used. Quality assurance also makes sure that there is 
stability data to support retest or expiration dates and storing conditions.  (Anderson, M. 
2000, 7-8; Guide to good manufacturing practice for medicinal products part I. 2009, 3; 
Skubch & Zimmer 2009, 27.)  
 
Implementing quality assurance in to the organization have generally long lasting 
positive impact on organization culture, if quality system have  quantifying 
measurement tools to detect it’s significance and usability (Silimperi, Franco, 
Veldhuyzen van Zanten & Macaulay 2002, 72). Quality assurance should also ensure 
that regular internal audits are performed, and that possible changes are approved before 
they are implemented in practice. Quality assurance task fields are typically accounting 
for 70% of total vaccine development and production time (Pora 2007, 33). In the light 
of this information, it can be said, that QA activities are very essential and requires 
resources to ensure that all quality assurance functions are appropriately implemented.   
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2.2 GLP and GMP 
 
Good Laboratory Practice (GLP) embodies a set of principles that provides a framework 
within which laboratory studies are planned, performed, monitored, recorded, reported 
and archived. Pre-clinical development is a stage of research that begins before clinical 
trials (testing in humans) can begin, and during which important data with regard to the 
safety and efficacy of a product is generated. (http://www.labcompliance.com, 2010.) 
 
GLP requirements are requested to be followed for all non-clinical safety studies that 
support clinical trial applications with investigational use only products or in support of 
marketing authorization applications submitted to Food and Drug Administration 
(FDA), or to European Medicines Agency (EMEA),  or by similar other national 
agencies. (http://www.labcompliance.com, 2010.) Good manufacturing practice (GMP) 
is applied when production for clinical trials is initiated.  
 
GMP regulates both production and quality control of a product. GMP is for ensuring 
that the drug manufacturing process is capable to consistently produce a product of 
required quality requirements in accordance to pre-determined specifications. 
Laboratory personnel should be aware of the principles of GMP that affect them and 
receive initial and continuous training concerning these specific GMP work practices. 
Laboratory facilities should be well designed with suitable premises and preferably be 
designed in such a way that it will allow a logical production and material flow in 
accordance to the specific cleanliness levels requirements. Their layout and design 
should minimize the risk of errors, contamination and cross-contamination of the 
product. (Guide to good manufacturing practice for medicinal products part I. 2009, 11.) 
Biggest difference between GLP and non-GLP work is the type and amount of 
documentation needed. Characteristic for GLP requirements is that they are study based 
while the GMP requirements are process based (Stanescu, I. 2010. Personal 
consultation). 
 
Different development phases require different quality requirements. Picture 1 in the 
next page illustrates the drug development phases in a pharmaceutical company. As 
seen from the picture, quality requirements evolve from the least regulated drug 
discovery to GLP regulated preclinical development phase.  
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When a company intends to conduct clinical trials and enters the product manufacturing 
phases, these stages are regulated by the Good Clinical Practice (GCP) and Good 
Manufacturing Practice (GMP). (http://www.labcompliance.com, 2010.) 
 
Picture 1. Drug development phases (http://www.labcompliance.com, 2010).  
  
 
2.3 GLP/GMP laboratory characteristics 
 
It is very typical that new projects frequently start in the pharmaceutical company wich 
is focused to research and development activities. New projects might change the need 
of laboratory configurations, case-work, equipment, utilities, associated capacities and 
personnel resources. Some pharmaceutical research laboratories might change layout 
even several times a year. It is clear, that due to the special requirements of the projects, 
companies have to customize their laboratories for their new purposes and according to 
the new quality requirements. (Traknyak 2006, 42, 48.) 
 
There are four general laboratory function categories; basic laboratories, laboratory 
support facilities, offices and personnel support facilities. Laboratories can be 
categorized in numerous types according to their functions. Typical examples of 
pharmaceutical biotechnology laboratories are microbiological laboratory, molecular 
biology- and cell culture laboratory, and chemical laboratory. Laboratory support 
facility includes for example equipment and storage rooms, glassware wash rooms, 
chemical storage rooms and waste rooms. (Diberardins, Gatwood, Baum, Groden, First 
& Seth 1987, 13.) 
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A significant number of procedures in pharmaceutical laboratories are less complex, but 
delicate, requiring extremely careful sample handling. Quality control laboratory 
process includes different samples, reagents and different levels of investigations 
involving various automated and manual methods. Analyses are performed in 
specialized working cells using sophisticated equipments and computers (eg. separative 
methods such as chromatography, electrophoresis or image analysis) or activities 
requiring a controlled environment such as cell culture or DNA characterization based 
assays. All though some experiments and equipments may be similar with the cell 
biology, molecular biology and biomedical research laboratories, they may differ from 
the experiments and equipments point of view. Analytical activities should also have 
specific proper support system for logistical and engineering activities. (Truchaud, Le 
Neel, Brochard, Malvaux, Moyon & Cazaubiel 1997, 1710.)  
 
Different laboratory models are more flexible than another. Single corridor laboratory 
model is a typical laboratory type in small units, and in this type of laboratory, the areas 
on both sides are same width and rooms are located on both sides of the central corridor. 
Under 20 year old laboratory facilities have also usually central corridor enough wide to 
accommodate for example cabins or refrigerators. Laboratories are usually fixed 
models, and modification of the laboratories is therefore rather difficult without 
constructive change. (Griffin 1998, 32-33.)       
 
Many special laboratory research and analysis functions are performed manually on a 
laboratory bench.   Typically workbenches are arranged so called “peninsula benches” 
at the right angles to the window walls. This arrangement creates working cells free 
from through-traffic. Work aisle is the floor space between the laboratory benches. 
Equipments and computers occupy significant laboratory bench space and shelves 
above peninsula benches are usually occupied by reagents and materials. Picture 2 on 
next page illustrates, a typical fixed laboratory model. (Griffin 1998, 21.)  
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Picture 2. Laboratory module (Griffin 1998, 21). 
 
 
Storage of laboratory supplies are usually accommodated under the workbench, on the 
shelves at the back of the workbench, or in the glass fronted wall cabins. Recently due 
to the safety awareness, laboratory designers have favored full height wall storage 
cabinets with the doors and shelves in the operation height. Reaching over and across 
the instruments on benches for reagents is considered hazardous for personnel and 
instruments. Also reaching and bending down under or above the laboratory table is 
considered to be not only un-ergonomic, but also be hazardous for equipments and to 
the personnel passing by. (Griffin 1998, 48.) Under laboratory tables, there should be 
sufficient amount of free space for the legs and laboratory chairs should be capable to 
be modified for different users. In general, laboratory systems, equipments, materials 
and reagents should be placed into same room, if possible and extra traffic between 
laboratory rooms should be avoided. 
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Good reliability in laboratory analysis is greatly influenced by a control and traceability 
of environmental factors such as temperature and humidity. In clinical chemistry, or 
molecular biology, where methods are able to reach a very low detection limit for the 
analyte determination, environmental control is essential for the success of the 
laboratory analyses. Another issue is biosafety, which has two aspects in the laboratory; 
prevention of sample contamination and prevention of personnel exposure to hazardous 
materials. Laboratory should be organized taking into account the needed biosafety 
requirements in a manner, that implementation of microbiological work and waste 
management operation is safe, easy and fast. (Biosafety in Microbiological and 
Biomedical Laboratories 2009, 27; Truchaud, et.al 1997, 1712.) 
 
 
2.4 Laboratory safety 
 
Pharmaceutical companies are imposed to follow many standards, good laboratory 
practices and work safety related laws for ensuring the safety of the personnel. 
Laboratory safety have also wider aspects; which contains product safety for the patient, 
laboratory personnel safety risks, environment control factors, organization chemical 
management and waste system and laboratory safety culture.   
 
 
2.4.1 Safety regulations in the pharmaceutical laboratory 
 
In the pharmaceutical industry, the laboratory safety has played an important role in the 
good manufacturing practices since regulations were established in 1978. A guide to a 
good manufacturing practice from year 1982 states, that pharmaceutical companies 
should have a safety program, which is including detection of hazardous materials, 
training of the personnel and safety inspection teams to audit work areas periodically. It 
also recommends organizations to encourage laboratory personnel to be in the 
discussions with managers to improve the quality control and safety. It was also 
recognized, that personnel’s active role had a positive correlation between work 
satisfaction, productivity, and the desire of the worker to perform assigned tasks. 
(Willig, et.al. 1982, 18, 20.)  
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Over the last two decades, significant changes in the pharmaceutical regulations have 
occurred and resulted in the adjustment of the original regulations to the current 
situations. The Food and Drug Administration’s (FDA) concept paper “Pharmaceutical 
cGMP’s of the 21st Century”: A Risk-Based Approach” forced companies to evaluate 
and focus more on risk assessments and laboratory safety of their critical operations. 
(Ahmed, Baseman, Ferreira, Genova, Harclerode, Hartman, Kim, Londeree, Long, 
Miele, Ramjit, Raschiatore & Tomonto 2008, 1.) Despite of the increased regulation, we 
have to admit that the manufacturing and use of a drug entails always some degree of 
risks for the patients. Risks should be evaluated throughout the risks of the product 
lifecycle from the beginning of the manufacturing process to the end user and disposal 
of the product. (ICH Guideline Q9, 1.) Product contamination and prevention of the 
personnel exposure to the hazardous substances could be together evaluated through the 
laboratory risk assessments. Quality Control implementation and follow up is essential 
for ensuring that the product risk for the patient is not increased. Pharmaceutical 
companies risk assessment strategies may vary, but their purpose is always to detect risk 
factors in a best possible way. 
 
Due to the unique laboratory practices, safety requirements and research applications 
per laboratory, safety and health considerations must be evaluated on a case-by-case 
basis (Modica 2007, 24). Although laboratory accidents seldom reach the public media, 
statistics shows that serious laboratory accidents do happen and small laboratory 
accidents are quite common, despite of the basic laboratory safety training of the 
personnel (Diberardins et.al. 1987, 2). It is recommended, that pharmaceutical 
laboratories should evaluate their laboratories from the operations and maintenance 
perspective for ensuring personnel awareness of safe laboratory practices. A 
comprehensive safety program and chemical management that includes medical 
surveillance, hazardous material control and hazardous work detection as well as proper 
waste management is essential in pharmaceutical company for a good laboratory safety. 
(Modica 2007, 25-27.)  
 
Chemical management is also detected to be cost-efficient in improving organization of 
chemical usage and therefore waste management is often supported by the company’s 
managers (Tischer & Scholaen 2003, 573).   
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Detailed safety instructions are given in a separate guidelines, standards and safety laws. 
Each country has own national regulations and it should be noted, that in the case a 
pharmaceutical company is planning to operate internationally, it is wise to predict 
regulations and fulfill international or target country requirements already from at the 
beginning. This requires knowledge of different national requirements and continuous 
follow-up of international and country specific regulations development. (Karinen 2002, 
10.)   
 
 
2.4.2  Laboratory work safety culture  
 
Another important laboratory safety issue is the laboratory work safety culture. 
Following questions should be evaluated:  How easy laboratory mistakes endanger 
another laboratory worker or product safety are reported to the manager? Is there a risk 
not to report or correct the item due to avoiding criticism or disciplinary action by the 
managers? Does the laboratory personnel share a common language to communicate 
with? For example along with the language barriers, acceptable safe practices in another 
country may not be compatible with safe practices in the host country. (Modica 2007, 
30.) Laboratory personnel might also have difficulties for understanding the 
significance of adverse events, or risk factors if they do not understand the matter, 
where item is related (Reed, Kim, Farquharson & Astion 2008, 959, 961-962). 
Therefore, support and fluent collaboration and discussions between the personnel and 
management is needed for the explanation of the risks and how to reduce it.  
 
Organization culture may have a negative or positive impact on how new practices are 
adopted in the organization. It is said, that the organization culture has its own history 
and it has been formed on the personnel relationships and management practices. When 
performing changes, one should also know organization specific culture environment 
and perform changes by respecting it.  (Vartola 2004, 126.) It is always better if there is 
sufficient time and resources to plan and do the changes jointly with the personnel. 
Authoritarian style should be avoided whenever possible, since by this way personnel’s 
motivation for work is significantly lower. (Peltonen 2007, 136.)  
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Open discussions and common agreements between personnel and management, as well 
as innovative, self-aware and self-learning working communities are seen as the most 
efficient way to perform changes and lead in the work society (Graber 2006, S47; 
Harisalo 2008, 286-287).  
 
Laboratory personnel in the pharmaceutical industry have continuous training of the 
regulations affecting their work. However, knowing the regulations is not the same as 
applying them into practice. Like Dr. Edward Deming said, profound knowledge is a 
perception of the truth, which comes from a deep understanding. He has claimed: 
“Without theory, experience has no meaning. Without theory, one has no questions to 
ask”. (Fasser & Brettner 2002, 39.) Experience of the personnel can not bypass, but 
competence of the personnel is considered to be profound only if it is based on a 
theoretical knowledge. This enables personnel to make right decisions in their work and 
to understand why work has to be done according to GMP requirements.    
  
 
2.5 Audits 
 
Auditing is a widely used and popular quality improvement tool. In 2006, 
Pricewaterhouse Coopers survey detected that 50% of the U.S. companies (of all 
financial sectors) are using continuous auditing techniques and 31% of the rest intend to 
implement continuous auditing (Alles, Kogan & Vasarhelyi 2008, 196). The purpose of 
internal control activity is to ensure that the company is on course toward profitability 
goals and achievement (Gountaras 2009, 932-933). Audits should be conducted in order 
to monitor the implementation and compliance of the GLP/GMP principles and to 
propose necessary corrective actions. Furthermore, auditing is used for evaluating the 
effectiveness of the system in meeting the stated goals, and to identify opportunities for 
continuous improvement in the system.  
 
One measurement of effectiveness is the degree to which objectives are achieved in an 
efficient and economical manner. Inspections usually covers personnel matters, 
premises, equipment, documentation, production, quality control, distribution of the 
medicinal products, arrangements for dealing with complaints and recalls.  
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It should be examined at intervals following a pre-arranged program in order to verify 
their conformity with the principles of Quality Assurance. (Russell 2000, 37, 113; 
www.who.int 2010.) 
 
Internal audits should be conducted in an independent and detailed way by designated 
competent person(s) from the company which evaluate the compliance of the quality 
from different angles (Stanescu, I. 2010. Personal consultation). Auditors should be 
preferably familiar with the profession to be audited, but like Bowie et.al. (2008)  study 
showed, clinical audit specialists with the sufficient audit training could be as competent 
auditors, as specific professionals of the area (Bowie, McKay, Murray & Lough 2008, 
1041). The ethical issues associated for all parties of the audit should be also evaluated 
before conducting audits (Patel 2010, 33). The benefits of the audit include the ability of 
a service to identify deficiencies, areas of excellence and to develop appropriate 
recommendations that will promote change (Patel 2010, 29). However, despite many 
good results of auditing, Berk, Callaly & Hyland (2003) show, that if the monitoring of 
the implementation of audit recommendations is absent, the quality improvement 
activity might be left incomplete and all goals of quality improvement process is not 
achieved. (Berk, Callaly & Hyland 2003, 256).  
 
It seems, that quality auditing alone may not be sufficient method for laboratory 
utilization projects, but combining it to the staff education and supported by the 
administration and its feedback system, it increases the success of the laboratory 
utilization (Calderon-Margalit et.al. 2005. 243). Repeat cycles of the clinical audits 
combined with the personnel active role and the administrative support in improvement 
projects and empowerment of the personnel, increases the personnel competence and 
quality of the work unit (Ved & Coupe 2007, 294).  
 
Evaluation of work practices and quality do not always require auditing. Self-evaluation 
is a useful tool for experienced personnel to evaluate their own work. It is a useful 
method for soliciting information on that kind of questions, where the participants have 
the first-hand knowledge. It seems, that self-evaluation tool, especially combined to the 
survey, is a useful tool for evaluating work practices. It also gives first hand information 
for the personnel about the level of knowledge and easy the work society to focus on the 
future improvement targets. (Asadoorian & Locker, 2006. 965-968; Blok, Sleegers & 
Karsten 2008, 379; Tzavaras-Catzambas, et.al. 2002, 78.) 
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3.  AIM OF THE STUDY 
 
 
The aim of this study was: 
 
- To evaluate how to implement the appropriate quality requirements of different 
laboratory activities in accordance with GLP/GMP regulations. 
 
- To evaluate how to improve the laboratory system efficiency, working practices and 
work safety.  
 
- To study the impact of the laboratory optimization project for the laboratory 
utilization, work safety, work practices and quality requirements. 
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4. METHODS, MATERIALS AND STUDY PROCESS 
 
 
The research laboratory activities in FIT Biotech’s Finn-Medi 3 building was changed 
many times in the past years in a need to adapt new research projects. According to the 
principle of continuous improvement in pharmaceutical companies, Finn-Medi 3 
building laboratory premises were audited in June 2010.  The purpose of the first audit 
made on 9
th
 of June 2010 was to follow-up the cGMP compliance status of the QC 
laboratories and evaluate also the good laboratory practices in FIT gamma, specifically 
related to research and development activities.  
 
Totally 11 laboratory rooms were audited in the first audit in June 2010 according FIT 
Biotech’s internal audit procedure by the FIT Biotech’s Quality board. Average rate of 
the evaluated laboratories by four independent auditors was varying from 1 to 3, the 
average result being 2. None of the rooms were rated as 0 (unsatisfactory). Four rooms 
of eleven were rated as 1 (not up to acceptable standards), six rooms were rated as 2 
(adequate) and one room was rated as 3 (very good). Audit was covering all type of 
laboratories, eg. protein work laboratory, microbiological laboratory, chemical 
laboratory, molecular biology work laboratory, cell culture laboratories and bacterial 
work laboratory. Audit was also including storage areas and facility maintenance area. 
 
As a consequence of the audit, totally 7 out of 20 laboratory rooms were decided to be 
optimized for upgrading the quality level of the laboratories and to utilize the current 
usage of the premises. Selected rooms were decided to be optimized and rest of the 
rooms rated as 2 were evaluated and maintained according to the corrective action plan 
recommendations and rooms rated as 3 were maintained based on general maintenance 
procedure applied for the specific laboratory. For rating the laboratories, following rates 
were used in audit June 2010:  
 
0 = Unsatisfactory  Item/area/system is missing or implies serious quality/compliance 
errors 
1= Poor Item/area/system is weak and not complying with acceptable 
standards 
2= Adequate  Item/area/system meets basic standards 
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3=  Very good  Item/area/system is superior 
 
Practical work for making required changes was agreed to be conducted as part of the 
laboratory optimization project and required changes were made between August 2010 
and January 2011. For implementing the recommendations, the head of the quality 
control department supported and coordinated the laboratory optimization project. 
Optimization of the laboratories was decided to be performed from the beginning jointly 
with all the personnel working in the respective laboratories. The laboratory personnel 
had the chance first to evaluate the critical working steps, material flow and current 
work practices, as well as to assess the safety aspects per laboratory room for detecting 
any deficiencies and possible optimization targets.  
 
 
After this, the laboratory personnel made needed changes and modifications for the 
specific laboratory room during August 2010 and laboratory safety officer inspected 
changes at the end of September. After rearrangement, laboratory rooms risk 
assessments were updated for detecting any compliance or safety risks of changed room 
layouts.  
 
Personnel was informed before rearrangement, that made changes will be inspected as 
part of a periodic internal audit during spring 2011 and the self-evaluation of the impact 
of laboratory optimization on the quality, work efficiency and work safety will be done 
by introducing a volunteer based  questionnaire. 
 
For evaluation of the impact of laboratory optimization work done during Autumn 
2010, a follow-up audit was performed on 23
rd
 of March 2011. Following topics were 
evaluated by the FIT Biotech’s Quality board, representing the inspection team. Audited 
rooms were selected by the QA with the following inspection topics: 
 
1. Risk assessment reports 
2. Procedures applied as described in approved SOPs 
3. Sample flow and analyses related reports 
4. Equipment qualification and maintenance documents 
5. Out of specifications (OOS) results during 2010-2011.  
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First audited laboratory was functioning before optimization as a storage area for 
research purposes and was containing not used equipments and materials. Since some 
laboratories were detected to be overcrowded in previous audit, this room was taken 
into use and ordered to upgrade to GMP status.  
 
Second laboratory was shared between research and GMP activities prior to the 
optimization project. Laboratory status was shared also after the follow-up audit, but all 
equipment and materials in the room were now maintained according to the highest 
standards. The last two audited laboratories were not under optimization process and 
their quality status was stated to be the same as at the time of the first audit.     
 
Both audits were based on FIT’s own standard operating procedures (SOP) complying 
with the  GMP/GLP audit guidelines.  In both audits, results were collected and reported 
by the head of FIT Biotech’s Quality Assurance (QA). Results were presented as a 
report where observations were listed and proposal of corrective actions and question of 
compliance were stated.  
 
For evaluating the work safety, improvement of work practices and quality compliance 
quality, the survey was sent to the personnel participating in the laboratory optimization 
project on July 2011. The questionnaire layout and persons selected to participate in the 
survey were agreed jointly FIT Biotech. As part of the optimization of the survey, the 
questionnaire was pre-tested with one worker, who had taken part in the laboratory 
optimization work.  Pre-testing of the questionnaire was done by the one project worker 
and final version of the questionnaire was elaborated after pre-testing and discussions 
with FIT Biotech.  
 
The questionnaire was sent to 13 persons, who had taken part in the optimization work 
at least to some level, including persons from FIT Biotech’s administration, Quality 
Board and Fit Gamma laboratory personnel, as well as laboratory activities maintenance 
personnel. Answering to the questionnaire was decided to be voluntarily and without 
identification. Purpose of the questionnaire as well as instructions how to complete the 
queries were informed through e-mail. Questionnaire sheets were translated both in 
English and Finnish and they were sent to the personnel through the in-house post 
system. The duration for completing the forms was assigned not to exceed one month. 
Collection of the questionnaires and results were analyzed on August 2011 
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5.  RESULTS 
 
 
5.1 Laboratory audits 
 
As a consequence of the optimization process, totally 7 laboratory rooms were 
optimized. The optimization of the selected rooms consisted in upgrading the quality 
level, evaluation of work practices and safety of the laboratory. In the table below is 
presented in the laboratory room status before and after the laboratory optimization 
project. Research grade laboratory requirement is a laboratory where common good 
laboratory practice is followed, while GLP and GMP level laboratories have specific 
activities and need to meet the specific regulatory requirements. 
 
Table 1. FIT Biotech’s Gamma laboratory status before and after optimization. 
RG= research grade, GLP=good laboratory practice grade, GMP= good manufacturing practice grade 
Laboratory 
number 
Status before 
optimization 
Rationale for change Status after 
optimi- 
zation 
1 Shared RG/ 
GMP 
laboratory 
RG/GMP grade laboratory should be 
updated to GMP level, since work has 
to be done according highest 
standards.  
GMP 
 2 RG Nature of work has been changed to 
GLP 
GLP 
3 RG Area containing GMP and GLP 
material should be minimum GLP 
grade 
GLP 
4 
 
GMP/RG Nature of work has been changed to 
RG 
RG 
5 RG Nature of work has been changed to 
GMP 
GMP 
6 RG Nature of work has been changed to 
GLP 
GLP 
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7 RG Area containing GMP and GLP 
material should be minimum GLP 
grade 
GLP 
 
As a result in the follow-up audit, it was noted, that the quality level of the laboratories 
was improved to desired quality level. Only some quality related documentation work 
was still pending at the time of the second audit and one new functionality test was 
proposed for the extract hood located in one laboratory.  
 
As a result of the optimization project, premises were cleaned and available materials 
was mapped and introduced for further use. Not used, but available materials were 
categorized and stored accordingly or materials were found to be useful in another 
purpose. New storage follow-up system was established for the laboratory materials and 
awareness of consuming materials was improved. Storage area was re-organized for 
increasing the storage capacity. Not-in-use equipment was listed and some of them were 
located more efficiently. All equipment in the laboratory rooms was reviewed and not 
used equipments were located and recorded to storage. Used equipments were all 
maintained and documentation was upgraded to have at least GLP grade documentation. 
Also, equipment database was updated and maintained. All Finn-Medi 3 related risk 
assessments was updated taking into account all the safety aspects of the quality control 
laboratories as well as of the maintenance service area.   
 
After optimization project, research grade laboratory work was more clearly separated 
from the GMP level work and because of the re-organization of the work, the amount of 
the shared research grade and GMP grade laboratories was reduced. As a result, 
company was capable to use Finn-Medi 3 laboratory premises in their fully, optimized 
capacity. 
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5.2 Questionnaire results 
 
The questionnaire was containing a total of 20 questions related to laboratory quality, 
laboratory activities and safety. Suggested questions were designed and selected jointly 
with FIT Biotech’s team as described in chapter 4. Questionnaire was used as a self-
evaluation tool for the personnel taking to a part of the optimization work and as a 
feedback from the laboratory optimization process. Totally 7 persons out of 13 
answered the questionnaire and from 7 only four answered to all required questions.  
 
Since only four persons answered the survey, questionnaire results can be thought only 
indicative. However, from the questionnaire can be seen, that the need to have GMP 
compliant laboratories was understood well among people and introduced changes also 
stated well (question 1, 2 and 5). Also, changes were stated well, and most answered, 
that laboratory rearrangement supported the GMP compliance in Gamma very well or 
well.   People provided more “very well” or “well” answers also when they evaluated if  
they had the possibility to influence laboratory optimization work (questions 3 and 16), 
but when they were asked about the impact of the laboratory optimization project on 
their own work (question 6), most answered that it had only some influence. However, 
most answered, that work practices were improved rather well (20). According survey, 
different opinions and experience was appreciated during optimization process, and 
work practice was felt to be improved in Gamma. However, personnel evaluated, that 
optimization did not have major influence in their own work. The reason of this might 
be the lack of working with the optimization process, or general facility improvements 
was perhaps not be seen the way to improve the personal work practices. 
 
When asked about improvements of the laboratory safety and ergonomic topics, 
personnel evaluated it rather well improved (questions 9-13). According to the 
personnel, the storage area was mostly improved from facility area, but also the 
common system utilization was evaluated to be improved rather well. According to the 
results, the information flow in the laboratory was working rather well, but limited 
between different departments (question 14).  
 
In the questionnaire (table 2) in the next page is gathered the personnel feedback 
obtained. Number of specific box illustrates the number of the persons agreed with the 
claim.  
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Table 2. Questionnaire form and evaluation. 
Questions Very well  Well Some Not at 
all 
1.How well laboratory rearrangement supported 
the GMP compliance in Gamma?   
3 2 1  
2. How well did you find that rearrangement 
project was supporting company’s  quality goals? 
2 3 1  
3. How did you find that all opinions were taken 
into account in optimization project planning? 
2 2 2  
4. How well information flow worked in Gamma 
during rearrangement process? 
2 4 1  
5. Were chances in the work practices well 
stated?  
2 3 1  
6. How well you felt that because of this project, 
you had opportunity to influence for your own 
work? 
1 1 4  
7. How much you participate for the optimization 
of the laboratory work? 
 2 5  
8. How much you feel that you expanded your 
knowledge about for applying the GLP/GMP 
regulations to the laboratory work? 
2  1 2 
9. How waste handling is improved in FIT 
Gamma? 
 4 1  
10. How work safety is improved in Gamma?  4 2  
11.How  ergonomic aspects are taken into count 
in Gamma? 
 3 3  
12. How system utilization (space, equipments, 
reagents)  are now organized than prior to the re-
organization project? 
1 5 1  
13. How is the laboratory storage area improved? 3 3 1  
14. Did the project generate information for the 
other laboratories (outside of the QC) about 
available materials and equipments in Gamma? 
1 3 1 1 
15. How you feel, that your work efficiency is 
improved when working in Gamma?  
 2 3 1 
16. How well you think that your suggestions 
were taken into account in the optimization 
work? 
2 3 2  
17. How do you think that this optimization 
project increased the co-operation between 
different departments? 
1 1 4  
18. How well changes made were evaluated with 
you  before and after the project? 
1 2 3 1 
19. How well you get support during the 
rearrangement project in Gamma (extra hands or 
advices)? 
 3 2 1 
20. How well you think that work practices have 
improved in FIT Gamma? 
 4 2  
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6. CONCLUSIONS 
 
 
The objective of this study was to evaluate how to implement the appropriate quality 
requirements of different laboratory activities in accordance with GLP/GMP 
regulations. Additionally laboratory system efficiency, working practices and work 
safety was evaluated before and after the optimization of selected laboratories. At last 
the impact of the laboratory optimization process was studied through internal audits 
and feedback evaluation of the completed questionnaires. 
 
Totally 7 out of 20 laboratory rooms were optimized in the laboratory optimization 
project. Project was made with the collaboration of the personnel and was concerning 
many people from the different level of the organization. Rooms were critical from the 
quality control work as well as sample and material flow point of view. As seen from 
table 1, as a result of the optimization, the quality level of the Finn-Medi 3 premises was 
improved. All seven optimized rooms were having the designed quality level and 
function as planned at the time of the second audit. Some of the quality documentations 
were still pending, but under the progress. Safety of the laboratories was inspected after 
the rearrangement and noted to be sufficient. Audit method was noticed to be capable to 
detect even small deficiencies in the laboratory and was a sufficient method for 
detecting the quality level of the laboratories.  
 
The questionnaire was sent to the personnel five months after the second audit. All 
though the questionnaire was pretested, it was noticed that some personnel did not 
answer all the questions and many did not answer for the questionnaire at all. 
Questionnaire was instructed by e-mail and evidently there was further need of having 
additional instructions provided to increase the rate and interest of completing the 
queries. Also, survey was made during the holiday season and all though the assigned 
answering time was over one month, the questionnaire perhaps did not reach all parties. 
Answering five months after the optimization process could be also too long. Because 
the lack of numbers of answerers, results are rather indicative and not conclusive.  
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Personnel were very aware of the set quality requirement and they were interested to 
give own suggestions for improving work practices and also ready to implement 
changes in practice. According survey, different opinions and experience was 
appreciated during optimization process, and work practice was felt to be improved in 
Finn-Medi 3. However, personnel evaluated, that optimization did not have major 
influence in their own work. The reason of this might be the lack of working with the 
optimization project, or maybe general facility improvements not seen be seen the 
improvement of own practice. Also according survey, there might was a sign, of the 
lack of information flow between different departments.    
 
Project shows, that it is possible to develop further laboratory practices, quality level of 
the laboratories and safety of the laboratories, if all parties from the different 
organization level support and take part of the process.  As seen from the previous 
studies, quality auditing alone may not be sufficient method for performing laboratory 
utilization projects, but combining it to the staff education and supported by the 
administration and its feedback system, it increases the success of the laboratory 
utilization projects (Calderon-Margalit, Mor-Yosef, Mayer, Adler & Shapira. 2005. 
243). Project indicates, that it is essential to agree the common rules of the project 
management practices; like responsibilities, sharing information practices and 
distribution of work tasks in between the project workers before launching the project. 
Also the feedback system from both the audits and project work was found to be 
important, since by this way made changes and improvements can be documented and 
organization is learning from the previous experiences. Project show, that quality level 
of the laboratories can be improved without making constructive and often expensive 
changes in the laboratories. However, laboratory optimization is then limited due to the 
building and premises layout and in some cases work practices and safety can not be 
improved any further. Results of the questionnaire were leaving still open questions, 
wich could be studied further. For example, questions such; what are the items in the 
laboratory work what are changing most efficiently personnel own working practices or 
what are the best supportive items for achieving improvements for personnel work 
efficiency? The challenge of this project was to keep continuous, and from both sides 
reflective information flow between the project workers. According to this experience, 
the laboratory quality level, and work practices can be improved through audits and 
shared improvement project, if all parties are work jointly for it.  
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APPENDIX 1.  
The questionnaire. 
 
Tämä kyselylomake koskee FIT Gamman laboratoriotilojen uudelleenjärjestämistä, joka tapahtui 
syksyllä 2010. Kysely on lähetetty kaikille järjestelyyn osallistuneille. Kyselyn tarkoituksena on 
selvittää, millainen vaikutus laboratorioiden uudelleenjärjestelyllä on ollut työnteon ja 
työturvallisuuden kehittymiseen kannalta FIT Gammassa. Kyselyn tuloksia käytetään Heli 
Suurosen YAMK opinnäytetyössä. Kysymykset koskevat vain FIT Gammaa ja kyselyyn 
osallistuminen on täysin vapaaehtoista. Palauta kysely nimettömänä postilokeron vieressä 
sijaitsevaan palautuslaatikkoon. Kiitos osallistumisesta! 
 
Anna arviosi laittamalla rasti ruutuun:  
 
Kysymykset Erittäin 
hyvin 
Hyvin Hieman Ei ollenkaan 
1.Kuinka hyvin laboratorioiden uudelleenjärjestely 
täytti GMP vaatimukset Gammassa? 
    
2. Tukiko uudelleenjärjestely mielestäsi yrityksen 
laatu tavoitteiden toteuttamista? 
    
3. Kuunneltiinko mielestäsi kaikkia osapuolia 
uudelleenjärjestelyn suunnittelussa? 
    
4. Tukiko tiedonkulku riittävän hyvin toimintaa 
uudelleenjärjestelyn aikana? 
    
5. Oliko toimintamuutokset mielestäsi riittävän hyvin 
perusteltuja?   
    
6. Koitko, että pystyit kehittämään omaa työtäsi 
projektin avulla? 
    
7. Kuinka aktiivisesti otit osaa laboratorioiden 
uudelleenjärjestely työhön? 
    
8. Koitko omaksuneesi jotain uutta tietoa GLP/GMP 
sääntöjen vaikutuksesta laboratoriotyöhön? 
    
9. Kuinka jätteiden käsittely on mielestäsi parantunut 
Gammassa? 
    
10. Kuinka työturvallisuus parantunut mielestäsi 
Gammassa? 
    
11. Kuinka ergonomia on mielestäsi huomioitu 
Gammassa? 
    
12. Kuinka tilat on organisoitu (laitteet, reagenssit) 
alkutilanteeseen nähden?  
    
13. Kuinka varastointitilat ovat parantuneet?     
14. Tuottiko projekti mielestäsi tietoa muille 
laboratorioille (QC:n ulkopuolelle) Gammassa 
saatavilla olevista materiaaleista ja laitteista? 
    
15. Edistikö järjestely työskentelysi tehokkuutta 
Gammassa? 
    
 
16. Onko ehdotuksesi mielestäsi otettu huomioon 
lopputuloksessa? 
    
17. Kuinka projekti mielestäsi lisännyt yhteistyötä eri 
osastojen välillä? 
    
18. Onko muutoksia käyty kanssasi läpi ennen ja 
jälkeen projektin? 
    
19. Saitko resurssitukea uudelleen- järjestelyn aikana 
(työtukea tai neuvoja)? 
    
20. Kuinka toimintatavat ovat parantuneet 
Gammassa? 
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This questionnaire is for the feedback of the laboratory optimization project, made during 
autumn 2010. This questionnaire is send to all personnel involved with the rearrangement 
project. Purpose of this questionnaire is to evaluate the impact of the laboratory 
rearrangement for work practices and work safety in FIT Gamma. Results are evaluated briefly 
in Heli Suuronen’s master’s degree thesis. Answering for this question is totally volunteering, 
and questions are concerning only FIT Gamma. Return this questionnaire unidentified to the box 
beside the mailboxes. Thank You for your effort!  
 
Please, estimate by marking X to the box.  
 
Questions Very well  Well Some Not at 
all 
1.How well laboratory rearrangement supported 
the GMP compliance in Gamma?   
    
2. How well did you find that rearrangement 
project was supporting company’s  quality goals? 
    
3. How did you find that all opinions were taken 
into account in optimization project planning? 
    
4. How well information flow worked in Gamma 
during rearrangement process? 
    
5. Were chances in the work practices well 
stated?  
    
6. How well you felt that because of this project, 
you had opportunity to influence for your own 
work? 
    
7. How much you participate for the optimization 
of the laboratory work? 
    
8. How much you feel that you expanded your 
knowledge about for applying the GLP/GMP 
regulations to the laboratory work? 
    
9. How waste handling is improved in FIT 
Gamma? 
    
10. How work safety is improved in Gamma?     
11.How  ergonomic aspects are taken into count 
in Gamma? 
    
12. How system utilization (space, equipments, 
reagents)  are now organized than prior to the re-
organization project? 
    
13. How is the laboratory storage area improved?     
14. Did the project generate information for the 
other laboratories (outside of the QC) about 
available materials and equipments in Gamma? 
    
15. How you feel, that your work efficiency is 
improved when working in Gamma?  
    
16. How well you think that your suggestions 
were taken into account in the optimization 
work? 
    
17. How do you think that this optimization 
project increased the co-operation between 
different departments? 
    
18. How well changes made were evaluated with 
you  before and after the project? 
    
19. How well you get support during the 
rearrangement project in Gamma (extra hands or 
advices)? 
    
20. How well you think that work practices have 
improved in FIT Gamma? 
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